Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gi-Ag@NMOF-CS-FA
- Development stage
- Preclinical
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**Gi-Ag@NMOF-CS-FA** is an experimental folic-acid-targeted chitosan-coated metal-organic-framework nanocomposite containing in-situ green-synthesized silver nanoparticles. It was reported as a bifunctional nanocarrier intended for detection and treatment of colon cancer cells. In an in-vitro study using HCT116 colon cancer cells and HGF normal cells, the folic-acid-functionalized formulation showed preferential cancer-cell targeting and reduced HCT116 viability, while displaying limited short-term toxicity toward HGF cells. The material remains an early preclinical nanomedicine concept and is not an approved therapeutic product.
02
Targets
FOLR1 (FRα)
Beyond the preview
Go deeper on Gi-Ag@NMOF-CS-FA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gi-Ag@NMOF-CS-FA.